Intellectus Partners, LLC Crispr Therapeutics Ag Transaction History

Intellectus Partners, LLC

$383 Million
Q3 2024

A detailed history of Intellectus Partners, LLC transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Intellectus Partners, LLC holds 6,881 shares of CRSP stock, worth $356,986. This represents 0.08% of its overall portfolio holdings.

Number of Shares

6,881

Previous 6,756 1.85%

Holding current value

$356,986

Previous $364,000 11.26%

% of portfolio

0.08%

Previous 0.1%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 06, 2024	BUY	$44.62 - $62.75 $5,577 - $7,843	125 Added 1.85%	6,881 $323,000
Q2 2024 Jul 18, 2024	SELL	$51.17 - $68.18 $63,706 - $84,884	-1,245 Reduced 15.56%	6,756 $364,000
Q1 2024 May 03, 2024	SELL	$60.67 - $89.12 $42,772 - $62,829	-705 Reduced 8.1%	8,001 $545,000
Q4 2023 Feb 05, 2024	BUY	$38.62 - $72.18 $5,793 - $10,827	150 Added 1.75%	8,706 $544,000
Q3 2023 Oct 25, 2023	BUY	$45.39 - $59.0 $29,503 - $38,350	650 Added 8.22%	8,556 $388,000
Q2 2023 Jul 31, 2023	BUY	$43.47 - $67.77 $2,173 - $3,388	50 Added 0.64%	7,906 $443,000
Q1 2023 May 04, 2023	BUY	$41.0 - $56.12 $8,200 - $11,224	200 Added 2.61%	7,856 $355,000
Q4 2022 Feb 02, 2023	SELL	$39.19 - $65.67 $14,265 - $23,903	-364 Reduced 4.54%	7,656 $311,000
Q3 2022 Nov 14, 2022	SELL	$61.1 - $83.78 $50,102 - $68,699	-820 Reduced 9.28%	8,020 $524,000
Q2 2022 Aug 12, 2022	SELL	$43.23 - $73.83 $45,391 - $77,521	-1,050 Reduced 10.62%	8,840 $537,000
Q1 2022 May 16, 2022	SELL	$53.19 - $79.24 $53,190 - $79,240	-1,000 Reduced 9.18%	9,890 $621,000
Q4 2021 Feb 14, 2022	SELL	$70.09 - $111.29 $19,625 - $31,161	-280 Reduced 2.51%	10,890 $825,000
Q3 2021 Nov 16, 2021	BUY	$110.2 - $156.64 $13,775 - $19,580	125 Added 1.13%	11,170 $1.25 Million
Q2 2021 Aug 13, 2021	BUY	$100.84 - $161.89 $88,235 - $141,653	875 Added 8.6%	11,045 $1.79 Million
Q1 2021 May 17, 2021	BUY	$110.72 - $210.04 $132,864 - $252,048	1,200 Added 13.38%	10,170 $1.24 Million
Q4 2020 Feb 18, 2021	BUY	$79.67 - $173.23 $626,763 - $1.36 Million	7,867 Added 713.24%	8,970 $1.37 Million
Q4 2020 Feb 12, 2021	SELL	$79.67 - $173.23 $664,607 - $1.45 Million	-8,342 Reduced 88.32%	1,103 $1.37 Million
Q3 2020 Nov 16, 2020	BUY	$78.5 - $100.64 $29,045 - $37,236	370 Added 4.08%	9,445 $790,000
Q2 2020 Aug 14, 2020	BUY	$38.5 - $76.05 $1,155 - $2,281	30 Added 0.33%	9,075 $667,000
Q1 2020 May 14, 2020	BUY	$33.68 - $62.53 $78,306 - $145,382	2,325 Added 34.6%	9,045 $384,000
Q4 2019 Jan 24, 2020	BUY	$36.68 - $73.13 $246,489 - $491,433	6,720 New	6,720 $409,000
Q2 2019 Aug 08, 2019	SELL	$35.45 - $48.2 $47,857 - $65,070	-1,350 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$28.02 - $40.87 $23,817 - $34,739	850 Added 170.0%	1,350 $48,000
Q3 2018 Nov 15, 2018	SELL	$44.35 - $65.71 $6,652 - $9,856	-150 Reduced 23.08%	500 $22,000
Q2 2018 Aug 14, 2018	BUY	$42.62 - $73.59 $27,703 - $47,833	650 New	650 $38,000
Q3 2017 Nov 14, 2017	SELL	$16.75 - $20.66 $7,118 - $8,780	-425 Closed	0 $0
Q2 2017 Aug 15, 2017	BUY	N/A	425	425 $7,000

Others Institutions Holding CRSP

# of Institutions

499

Shares Held

56.8M

Call Options Held

1.7M

Put Options Held

1.8M

View Full List

About CRISPR Therapeutics AG

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $4.05B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

More about CRSP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Intellectus Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Intellectus Partners, LLC with notifications on news.

Account

Intellectus Partners, LLC Crispr Therapeutics Ag Transaction History